LYEL vs NUVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LYEL Captures Institutional Edge (2โ1 Pillars ยท 2โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lyell Immunopharma, Inc. Common Stock (LYEL) driven by superior Momentum & Technical, Options & Structure while NUVB counters with relative strength in Growth & Margin. Fundamentally, LYEL trades at N/M Forward P/E with -1341693.4% operating margin (-80.0% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, LYEL sits in SURGE (58th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYEL Revenue | NUVB Revenue | LYEL Op. Margin | NUVB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -15538.7% | N/A | LYEL |
| FY2020 | $10M | N/A | -2732.6% | N/A | LYEL |
| FY2021 | $10M | N/A | -2016.7% | N/A | LYEL |
| FY2022 | $80M | N/A | -220.9% | N/A | LYEL |
| FY2023 | $0M | N/A | -190006.2% | N/A | LYEL |
| FY2024 | $0M | $10M | -588123.0% | -7527.3% | NUVB |
| FY2025 | $0M | $60M | -748344.4% | -338.7% | NUVB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYEL | NUVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $434.8M | $1.3B | Larger Scale | NUVB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -80.0% | +242.6% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -1341693.4% | -61.2% | Higher Margin | NUVB |
| Net Profit Margin Profitability | 0.0% | -67.4% | Higher Margin | LYEL |
| Return on Equity (ROE) Capital Efficiency | -97.8% | -49.1% | Higher ROE | NUVB |
| 52-Week Range Position Momentum | 18% ($7โ$45) | 2% ($4โ$10) | Stronger Trend | LYEL |
| Beta / 30D Volatility Risk Regime | 1.62ฮฒ ยท 163% Vol | 1.52ฮฒ ยท 55% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 35.1 / 100 (SELL) | 61.0 / 100 (BUY) | Higher Composite | NUVB |